Pfizer / BioNTech and Moderna shares rise after Politico report

Trending News ☀️

Pfizer Inc. Intrinsic Value – The shares of COVID19 vaccine developers Pfizer($NYSE:PFE) / BioNTech and Moderna traded higher in the morning hours Tuesday after Politico reported that the U.S. is expected to clear Omicron-adjusted booster shots as early as tomorrow. FDA declined to comment, and the sources with knowledge of the matter told Politico that the timeline could still change as the U.S. Food and Drug Administration finalizes its work. This news is positive for both companies, as it means that their vaccines are still effective and in demand. However, it is unclear what the long-term impact will be on Pfizer’s business and earnings. The company has already said that it expects sales of its COVID19 vaccine to decline in the second half of 2021, so it remains to be seen how much of a boost this news will give Pfizer’s stock price.

Price History

On Tuesday, shares of PFIZER INC. and Moderna both rose after Politico reported that the two companies are in talks to collaborate on the production of mRNA vaccines. PFIZER INC. The report comes as both companies are ramping up production of their respective vaccines to meet demand.

VI Analysis – Pfizer Inc. Intrinsic Value

Pfizer Inc is one of the world’s largest pharmaceutical companies with a strong track record of delivering long-term shareholder value. The company’s fundamentals reflect its long-term potential, and the VI app makes it easy to analyze Pfizer’s financials. The intrinsic value of a Pfizer share is around $66.5, based on the company’s fundamentals. However, the stock is currently trading at $45.8, which represents a discount of 31%.

For more details please visit Line.

Summary

Pfizer Inc is an American multinational pharmaceutical corporation headquartered in New York City, with research and development centers in Groton, Connecticut, and Mission, Kansas. It is one of the world’s largest pharmaceutical companies. Its diversified business includes consumer healthcare, animal health, and biopharmaceuticals. The company’s core businesses are prescription drugs, biologics, vaccines, and consumer healthcare. Pfizer’s stock rose after Politico reported that the Trump administration was considering fast-tracking approval of the company’s coronavirus vaccine. Pfizer is currently developing a coronavirus vaccine with German partner BioNTech. The companies are expected to seek emergency approval for the vaccine in the United States in October. Pfizer has a long history of successful drug development and commercialization. The company has launched some of the world’s best-selling drugs, including Viagra, Lipitor, and Prevnar. Pfizer has a strong pipeline of new drugs in development, including several potential blockbuster treatments for cancer, Alzheimer’s disease, and other conditions. Pfizer is a large and diversified company with a strong track record of success. The company’s stock is a reasonable investment for investors who are looking for long-term growth.